Top Markets
#1 Helium Helium +110.72%
#2 MowCat MowCat +102.94%
#3 Seeker Seeker +91.30%
#4 AI XOVIA AI XOVIA +57.72%
#5 Pons Pons +53.06%
#6 UnifAI Network UnifAI Network +30.76%
#7 Bounce Bounce +28.80%
#8 pipedog pipedog +22.85%
#9 Zylo Ecosystem Zylo Ecosystem +21.54%
#10 Tensor Tensor +19.50%
Coin of the day
Helium Helium
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Classement en actions #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Prix de l'action
$8.74
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$699.74M
Changement (1 jour)
-4.85%
Changement (1 an)
-2.29%
Pays
US
Échange BridgeBio Oncology Therapeutics Inc. (BBOT)

Catégorie

Healthcare
Bénéfices pour BridgeBio Oncology Therapeutics Inc. (BBOT)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de BridgeBio Oncology Therapeutics Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour BridgeBio Oncology Therapeutics Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH